Evidence map›Paper›PMID 40672975›Full record

ArticleTherapeutic advances in gastroenterology2025

Clinical impact of recombinant thrombomodulin administration on disseminated intravascular coagulation due to severe acute pancreatitis (Recover-AP study).

Takeshi Ogura, Saori Ueno, Akitoshi Hakoda, Atsushi Okuda, Nobu Nishioka, Jun Sakamoto, Jun Matsuno, Yuki Uba, Mitsuki Tomita, Nobuhiro Hattori and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takeshi OguraAdvanced Pancreatobiliary Medical Center, Endoscopy Center, Osaka Medical and Pharmaceutical University, 2-7 Daigakuchou, Takatsukishi, Osaka 569-8686, Japan.ORCID https://orcid.org/0000-0003-2916-6568
Saori Ueno2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Akitoshi Hakoda2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Atsushi Okuda2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Nobu Nishioka2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Jun Sakamoto2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Jun Matsuno2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Yuki Uba2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Mitsuki Tomita2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Nobuhiro Hattori2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Junichi Nakamura2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Kimi Bessho2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Taro Iwatsubo2nd Department of Internal Medicine, Osaka Medical College Ringgold Standard Institution, Takatsuki, Japan.ORCID https://orcid.org/0000-0001-7721-8292
Ahmad F AboelezzGastroenterology and Hepatology Unit, Department of Internal Medicine, Tanta University, Egypt.
Hiroki Nishikawa2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: If severe acute pancreatitis (SAP) is complicated by disseminated intravascular coagulation (DIC) or walled-off necrosis (WON), the mortality rate may increase. Therefore, prevention of the development of WON and treatment of DIC are likely to play important roles in improving survival in SAP. Although recombinant human soluble thrombomodulin (rhTM) might play a useful role in treating DIC, the impact of rhTM on improving survival and resolution of DIC due to SAP is still unclear. Objective: This study aimed to evaluate the clinical impact of rhTM in patients with SAP and DIC. Design: A single-center retrospective study. Method: The patients were divided into two groups: the rhTM group and the non-rhTM group, in which rhTM was not administered. The primary outcome was the DIC resolution rate at 7 days after starting treatment. The mortality rate at 28 days was secondarily evaluated. Results: Among 321 SAP patients, 63 patients were complicated with DIC, and they were divided into rhTM ( Conclusion: In conclusion, rhTM may play a role not only in improving the resolution rate of DIC and improving the survival rate of SAP, but also in preventing the development of WON.

Indexed as

acute pancreatitisdisseminated intravascular coagulationendoscopic retrograde cholangiopancreatographyrecombinant thrombomodulinwalled-off necrosis

Identifiers

PMID40672975
PMCPMC12264407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.